¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Newsl Infant Feed Action Coalit"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
¿µ¹® infant ÇÑ±Û ¿µ¾Æ, À¯¾Æ, Á¥¸ÔÀÌ
¼³¸í   
  ½Å»ý¾Æ¸¦ Æ÷ÇÔÇØ Ãâ»ý ÈÄ 1³â±îÁöÀÇ ¾î¸°À̸¦ ¸»Çϸç ÀÌ ±â°£À» ¿µ¾Æ±â¶ó ºÎ¸¥´Ù. ½Åü¹ßÀ° ¹× ¿îµ¿±â´ÉÀÇ ¹ß´ÞÀÌ ¸Å¿ì È°¹ßÇÑ ½Ã±âÀÌ´Ù. ÀÌ ½Ã±â´Â ½Å»ý¾Æ ¶§ºÎÅÍ °è¼ÓÇØ¼­ È¯°æ¿¡ ÀûÀÀÇØ °¡´Â Áß¿äÇÑ ½Ã±âÀÌ´Ù. Á¥´Ï°¡ ³ª¿À¸ç ¸é¿ª±â´ÉÀǠȰ¼ºÈ­, ¹Ý»çÀÇ ¼Ò½Ç°ú ¼öÀǿÀÇ ¹ß´Þ, °¨°¢(½Ã°¢, Ã»°¢, Ã˰¢) ±â´ÉÀÇ ¹ß´Þ, Ã¼Áß°ú Å°ÀÇ Áõ°¡¸¦ È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ã¼ÁßÀº 3°³¿ù¿¡ 2¹è, 1³â¿£ 3¹è°¡ µÇ¸ç, Å°´Â 1³â¿¡ ¾à 27cm ÀÚ¶õ´Ù.
¿µ¹® sudden infant death syndrome ÇÑ±Û ¿µ¾Æ±Þ»çÁõÈıº
¼³¸í   
  ÇÑ »ì ÀÌÇÏÀÇ °Ç°­ÇÑ ¾Æ±â°¡ ¾Æ¹«·± Á¶ÁüÀ̳ª ¿øÀΠ¾øÀÌ °©Àڱ⠻ç¸ÁÇßÀ» °æ¿ì¿¡ ³»¸®´Â Áø´ÜÀÌ´Ù. ÀÌ ÁõÈıºÀº »ýÈÄ 1~4°³¿ù »çÀÌ¿¡ °¡Àå ¸¹ÀÌ ¹ß»ýÇϸç, ´ëºÎºÐ ¹ã 10½Ã¿¡¼­ ¿ÀÀü 10½Ã »çÀÌ¿¡ ¹ß»ýÇÑ´Ù. Á¶»êÇϰųª ºÎ¸ð°¡ Èí¿¬ÀÚÀÏ °æ¿ì, 20¼¼ ÀÌÇÏ »ê¸ðÀÇ ÃÊ»ê, ÀÓ½ÅÀü °Ç°­°ü¸®¿¡ ¼ÒȦÇÑ »ê¸ð¿¡°Ô¼­ Å¾ ¿µ¾Æ¿¡°Ô¼­ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. ÀÌ ÁõÈıºÀ¸·Î »ç¸ÁÇÑ ¿µ¾ÆÀÇ ÇüÁ¦ÀÏ °æ¿ì ÀϹÝÀûÀΠ¿µ¾Æº¸´Ù °É¸± È®·üÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • postmature infant
    °ú¼÷¾Æ
  • premature infant
    ¹Ì¼÷¾Æ, Á¶»ê¾Æ
  • sudden infant death syndrome
    ¿µ¾Æµ¹¿¬»çÁõÈıº
  • antifungal action
    Ç×Áø±ÕÀÛ¿ë
  • antimicrobial action
    Ç×±ÕÀÛ¿ë
  • antipyretic action
    ÇØ¿­ÀÛ¿ë
  • action
    1. ÀÛ¿ë 2. Ȱµ¿
  • action current
    Ȱµ¿Àü·ù
  • action potential
    Ȱµ¿ÀüÀ§
  • action tremor
    Ȱµ¿¶³¸²
  • additive action
    ºÎ°¡ÀÛ¿ë
  • adverse action
    À¯ÇØÀÛ¿ë
  • absorption action
    Èí¼öÀÛ¿ë
  • amphoteric action
    ¾çÂÊÀÛ¿ë
  • anabolic action
    ÇÕ¼º´ë»çÀÛ¿ë, µ¿È­ÀÛ¿ë
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • pharmacological action
    ¾à¸®ÀÛ¿ë
  • promotor action
    ÃËÁøÀÛ¿ë
  • action potential
    Ȱµ¿ÀüÀ§
  • action tremor
    Ȱµ¿¶³¸²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • macerated infant
    ħ¿¬¿µ¾Æ, ¿¬È­¿µ¾Æ
  • mature infant
    ¸¸»è¾Æ, ¸¸±â»ê¾Æ, ¸¸±â½Å»ý¾Æ
  • newborn infant
    ½Å»ý¾Æ
  • nursing infant
    ¾çÀ°¿µ¾Æ, ¼öÀ¯¿µ¾Æ, À°¾Æ
  • premature infant
    ¹Ì¼÷¾Æ, Á¶»ê¾Æ
  • sudden infant death syndrome
    ¿µ¾Æ±Þ»çÁõÈıº
  • action
    Ȱµ¿, ÀÛ¿ë
  • absorption action
    Èí¼öÀÛ¿ë
  • action current
    Ȱµ¿Àü·ù
  • action potential
    Ȱµ¿ÀüÀ§
  • action tremor
    Ȱµ¿¶³¸²
  • additive action
    ºÎ°¡ÀÛ¿ë
  • adverse action
    À¯ÇØÀÛ¿ë
  • amphoteric action
    ¾ç¼ºÀÛ¿ë
  • anabolic action
    µ¿È­ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • infant feeding bottle
    Æ÷À¯º´(øÔêáܺ).
  • infant feedings
    ¿µ¾Æ¿µ¾ç(?ä®ç½å×).
  • infant food
    ¿µ¾Æ½Äǰ(¡­ãÝù¡).
  • infant health
    ¿µ¾Æº¸°Ç(ÊþËâËÓ˧).
  • infant health
    ¿µ¾Æº¸°Ç(?ä®ÜÁËí).
  • infant mobilization device
    ¿µ¾Æ À̵¿ ÀåÄ¡
  • infant mortality rate
    ¿µ¾Æ»ç¸Á·ü.
  • infant nutrition
    ¿µ¾Æ¿µ¾ç.
  • infant sleep apnea
    ¿µ¾Æ ¼ö¸é ¹«È£ÈíÁõ
  • infant ³ª infans
    ¿µ¾Æ( ä®), À¯¾Æ.
  • infant-mother interaction
    ¿µ¾Æ-¸ð »óÈ£ÀÛ¿ë
  • premature infant
    ¹Ì¼÷¾Æ(Ú±âÙä®), Á¶»ê¾Æ(ðÄß§ä®).
  • HT2 receptors, action of hallucinogens
    5-ÇÏÀ̵å·Ï½ÃÆ®¸³Å¸¹Î2¼ö¿ëü
  • SDA= specific dynamic action
    ƯÀ̵¿Àû ÀÛ¿ë.
  • absorption action
    Èí¼öÀÛ¿ë.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • infant feeding bottle
    Æ÷À¯º´(øÔêáܺ).
  • infant feedings
    ¿µ¾Æ¿µ¾ç(?ä®ç½å×).
  • infant food
    ¿µ¾Æ½Äǰ(¡­ãÝù¡).
  • infant health
    ¿µ¾Æº¸°Ç(?ä®ÜÁËí).
  • infant health
    ¿µ¾Æº¸°Ç(ÊþËâËÓ˧).
  • infant mobilization device
    ¿µ¾Æ À̵¿ ÀåÄ¡
  • infant mortality rate
    ¿µ¾Æ»ç¸Á·ü.
  • infant nutrition
    ¿µ¾Æ¿µ¾ç.
  • infant sleep apnea
    ¿µ¾Æ ¼ö¸é ¹«È£ÈíÁõ
  • infant ³ª infans
    ¿µ¾Æ( ä®), À¯¾Æ.
  • infant-mother interaction
    ¿µ¾Æ-¸ð »óÈ£ÀÛ¿ë
  • low birth weight infant
    ÀúüÁßÃâ»ý¾Æ.
  • low birth wight infant
    ÀúüÁßÃâ»ý¾Æ(î¸ô÷ñìõóßæä®)
  • macerated infant
    ħ¿¬À¯¾Æ(öÙæãêêä®).
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý (ÇÐ)(ËÎËÛ ËâËôË×̰).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
VAT variable antigen type; ventricular accommodation test; ventricular activation time; vesicular amine ...
BSID Boyley Scales of Infant Development; Boyley À¯¾Æ ¹ß´Þ ôµµ
IMR Infant Mortality Rate; ¿µ¾Æ »ç¸Á·ü
KIDS Kansas Infant Development Screen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
WIC Women, Infant, and Children
SGA small for gestational age infant
VLBWI very low birth weight infant
ADFI Average daily feed intake
FC Feed consumption
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antagonistic action
    ±æÇ× ÀÛ¿ë
  • antidiuretic action
    Ç×ÀÌ´¢ÀÛ¿ë
  • antimicrobial action
    Ç×±Õ ÀÛ¿ë
  • antinociception action
    Ç×Ä§ÇØ¼ö¿ë¼º ÀÛ¿ë, Ç×À¯ÇØ ¼ö¿ë¼º ÀÛ¿ë
  • antipyretic action
    ÇØ¿­ ÀÛ¿ë
  • antispasmodic action
    Áø°æÀÛ¿ë
  • bactericidal action
    »ì±Õ ÀÛ¿ë, »ì±Õ¼º
    1. ¹ÚÅ׸®¾Æ¸¦ Á×ÀÌ´Â Çö»ó. ÀÌ ¿ë¾î´Â Á¾Á¾ Ç×»ýÁ¦ÀÇ ¼º°ÝÀ» ¼³¸íÇϴµ¥ »ç¿ëµÈ´Ù. 2. È­Çпä¹ýÁ¦, ¼Òµ¶Á¦ Áß¿¡´Â ¹Ì»ý¹°À» ¼Ò¸ê½ÃŰ´Â ÀÛ¿ëÀÌ ÀÖ´Ù. ÀÌ¿¡ ´ëÇØ ¾î¶² ¾àÁ¦¿¡ ´ëÇØ ±ÕÀÇ Áõ½ÄÀÌ ¾ïÁ¦µÇ´Âµ¥ ¾àÁ¦¸¦ Á¦°ÅÇÏ¸é ´Ù½Ã Áõ½ÄÇÏ´Â °ÍÀ» Áõ±Õ ÀÛ¿ëÀ̶ó ÇÑ´Ù.
  • bacteriostatic action
    Á¤±Õ ÀÛ¿ë
    ¼¼±ÕÀÇ ¹ßÀ° ¶Ç´Â Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â ÀÛ¿ë.
  • biological action
    »ý¹° ÀÛ¿ë
  • buffer action
    ¿ÏÃæ ÀÛ¿ë
  • calorigenic action
    ¿­ »ý»ê ÀÛ¿ë
    À½½Ä¹° ¶Ç´Â À½½Ä¹° ¼ººÐ¿¡ ÀÇÇØ ü³»¿¡ ¹ß»ýÇÑ ÃÑ ¿¡³ÊÁö·®.
  • cause of action
    ¼Ò¼ÛÀÇ ¿øÀÎ
    ´ëºÎºÐ, ¹ýÀû Á¶Ä¡ÀÇ ¹è°æÀ̳ª ÀÌÀ¯¸¦ ÀǹÌÇÑ´Ù. ¹ýÀû ¹è»óÀ» ÇÏ¿©¾ß ÇÏ´Â À߸øµÈ ¿øÀÎ.
  • central action
    ÁßÃß ÀÛ¿ë
  • chronotropic action
    º¯µ¿ ÀÛ¿ë, º¯½Ã ÀÛ¿ë
  • ciliary action
    ¼¶¸ð ÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
prolonged action tablet sustained action tablet
sparing action The manner in which a nonessential nutritive component, by its presence in the diet, lowers the dietary requirement for an essential component; thus, nonessential l-cysteine spares essential l-methionine and nonessential l-tyrosine spares essential l-phenylalanine.
Synonym: sparing phenomenon.
(05 Mar 2000)
specific action The action of a drug or a method of treatment which has a direct and especially curative effect upon a disease, e.g., the action of vitamin B12 in pernicious anaemia.
(05 Mar 2000)
specific dynamic action The increase of heat production caused by the ingestion of food, especially of protein.
(05 Mar 2000)
delayed-action preparations Dosage forms of a drug that act over a period of time.
(12 Dec 1998)
thermogenic action Increase of heat production of the body, as by the thyroid hormone.
Synonym: thermogenic action.
(05 Mar 2000)
law of mass action <chemistry> This law states that the rate of a given chemical reaction is proportional to concentration of the reactants.
(09 Oct 1997)
Bayley Scales of Infant Development A psychological test used to measure the developmental progress of infants over the first two and one-half years of life; consists of three scales: mental, motor, and behaviour record.
(05 Mar 2000)
rate, infant mortality The number of children dying under a year of age divided by the number of live births that year. The infant mortality rate in the united states, which was 12.5 per 1,000 live births in 1980, fell to 9.2 per 1,000 live births in 1990.
(12 Dec 1998)
Cattell Infant Intelligence Scale A standardised scale for assessment of the cognitive development of infants between the ages of 3 and 30 months.
(05 Mar 2000)
mortality rate, infant The number of children dying under a year of age divided by the number of live births that year. The infant mortality rate in the united states, which was 12.5 per 1,000 live births in 1980, fell to 9.2 per 1,000 live births in 1990.
(12 Dec 1998)
postmature infant A baby born 1 week (7 days) or more after the usual 9 months (280 days) of gestation.
(12 Dec 1998)
post-term infant A baby born 2 weeks (14 days) or more after the usual 9 months (280 days) of gestation, as calculated from the last menstrual period (lmp). This is an important calculation, since, if delivery is delayed 3 weeks beyond term, the infant mortality rate skyrockets to 3 times normal.
(12 Dec 1998)
preterm infant An infant with gestational age of less than 37 completed weeks (259 completed days).
(05 Mar 2000)
stillborn infant An infant who shows no evidence of life after birth.
Compare: liveborn infant.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • force feed
    ¾Ð·Â ±ÞÀ¯
  • green feed(fodder)
    (¸¶¼ÒÀÇ)²Ã
  • action
    ¿òÁ÷ÀÓ,Çൿ,µ¿ÀÛ
  • action
    Ȱµ¿;ÀÛ¿ë;Çൿ;ÇàÀ§;µ¿ÀÛ;ÀÛ¿ë;¼Ò¼Û;ÀüÅõ;¼Ò¼³ÀÇ ÁٰŸ® Àü°³
  • civil action
    ¹Î»ç¼Ò¼Û
  • class action
    (°øµ¿ ÇÇÇØÀÚµéÀÇ)Áý´Ü ¼Ò¼Û
  • contact action
    Á¢ÃËÀÛ¿ë
  • covert action(operation)
    (°æÂû.Á¤º¸ºÎÀÇ)ºñ¹Ð°øÀÛ;ºñ¹Ðøº¸È°µ¿
  • cross action
    ¹Ý´ë ¼Ò¼Û;¹Ý¼Ò
  • delaying action
    Áö¿¬ Àü¼ú ÀÇ
  • direct action
    Á÷Á¢ Çൿ ±Ç¸®¸¦ À§ÇÑ ÆÄ¾÷(µ¥¸ð,½Ã¹ÎÀû ÀúÇ× µî)
  • disengaging action
    (±º)±³Àü ȸÇÇ;ÀÚ¹ßÀû ö¼ö
  • evasive action
    (Àü½Ã¿¡ ¼±¹Ú,Ç×°ø±â°¡ ÃëÇÏ´Â)ȸÇÇ Çൿ
  • friendly action
    ¿ìÈ£Àû ¼Ò¼Û
  • industrial action
    ³ëµ¿ÀÚÃøÀÇ ÀïÀÇ ÇàÀ§
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á